Results 31 to 40 of about 54,917 (299)
International Journal of Cardiology: Heart & Vasculature, 2022 Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in
Go Yokouchi +11 more
doaj +1 more source
Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns [PDF]
Exploration of MedicineSodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management.
Farazul Hoda +8 more
doaj +1 more source
Pharmaceutics, 2020 Since sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced blood glucose level by inhibiting renal tubular glucose reabsorption mediated by SGLT2, we aimed to investigate the pharmacokinetics and kidney distribution of DWP16001, a novel SGLT2 ...
Min-Koo Choi +5 more
doaj +1 more source
Journal of Clinical and Translational Science, 2022 OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli +5 more
doaj +1 more source
Targeting hypertension with SGLT2 inhibition: the EU-funded SGLT2 HYPE trial. [PDF]
Eur Heart JEitel I, Saraei R, Rawish E.
europepmc +3 more sources
Renoprotective Effects of SGLT2 Inhibitors [PDF]
Heart Failure Clinics, 2022 SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
openaire +3 more sources
Diabetic ketoacidosis with SGLT2 inhibitors [PDF]
BMJ, 2020 ### What you need to know A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy.
Musso, Giovanni +3 more
openaire +2 more sources
Medicines, 2022 Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul +4 more
doaj +1 more source
Development of SGLT1 and SGLT2 inhibitors [PDF]
Diabetologia, 2018 Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the ...
Timo Rieg, Volker Vallon
openaire +4 more sources
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Therapeutics and Clinical Risk Management, 2023 Gates B Colbert,1 Hector M Madariaga,2 Anna Gaddy,3 Mohamed E Elrggal,4 Edgar V Lerma5 1Texas A&M University College of Medicine at Dallas, Dallas, TX, USA; 2Department of Internal Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA ...
Colbert GB +4 more
doaj